All stock lists
CervoMed Inc. (NASDAQ:CRVO)
US · Delayed Price · Currency is USD
Also listed: DFFNHealthcare · Biotechnology
1.77+0.40 (+29.20%)
Market cap
$26.8M
Insider Score
Health Score
Analyst consensus
Listed since
May 23, 2008
Website
Insider Score
––Not scored
CRVO Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From CRVO’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$28.5M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $6.1M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $21.3M
- Current liabilities
- $4.0M
- Current ratio
- 5.37
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$26.6M
- Free cash flow
- -$26.6M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 15.1M
- Share growth (1y)
- 63.4%
- Cash runway
- 3 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CRVO Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $322.57 K | $0.00 |
| Revenue Growth (YoY) | -100.00 % | — | — | — | — | — |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $322.57 K | $0.00 |
| SG&A Expense | $2.43 M | $2.36 M | $2.98 M | $2.51 M | $2.33 M | $3.27 M |
| R&D Expense | $3.68 M | $4.32 M | $5.14 M | $5.83 M | $6.04 M | $5.11 M |
| Operating Expenses | $6.10 M | $6.68 M | $8.11 M | $8.33 M | $8.37 M | $6.62 M |
| Operating Income | -$6.10 M | -$6.68 M | -$8.11 M | -$8.33 M | -$8.04 M | -$6.62 M |
| Pretax Income | -$5.90 M | -$6.57 M | -$7.96 M | -$8.09 M | -$7.73 M | -$6.26 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$5.90 M | -$6.57 M | -$7.96 M | -$8.09 M | -$7.73 M | -$6.26 M |
| EPS (Basic) | -$0.39 | -$0.64 | -$0.86 | -$0.87 | -$0.84 | -$0.70 |
| EPS (Diluted) | -$0.39 | -$0.64 | -$0.86 | -$0.87 | -$0.84 | -$0.70 |
| Shares Outstanding | 15.12 M | 10.24 M | 9.26 M | 9.25 M | 9.25 M | 8.95 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.